Daniel Wetterskog

Plasma <i>AR</i> and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca et al. · Science Translational Medicine · 2015 · 441 citations · Full text

Medicine, Oncology, Pharmacology +14

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis

L. Johan Nissen, Renhai Cao, Eva–Maria Hedlund et al. · Journal of Clinical Investigation · 2007 · 284 citations · Full text

Medicine, Cancer Biology, Oncology +14

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

Konstantin J. Dedes, Daniel Wetterskog, Ana M. Mendes‐Pereira et al. · Science Translational Medicine · 2010 · 255 citations

Life Sciences, Molecular Biology, Oncology +15

Synthetic lethality of PARP inhibition in cancers lacking<i>BRCA1</i>and<i>BRCA2</i>mutations

Konstantin J. Dedes, Paul M Wilkerson, Daniel Wetterskog et al. · Cell Cycle · 2011 · 192 citations · Full text

Life Sciences, Molecular Biology, Oncology +17